

Nicolas Veziris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/316044/publications.pdf>

Version: 2024-02-01

123
papers

4,836
citations

109321

35
h-index

106344

65
g-index

152
all docs

152
docs citations

152
times ranked

4425
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834. | 13.7 | 452 |
| 2 | The Peptidoglycan of Stationary-Phase <i>Mycobacterium tuberculosis</i> Predominantly Contains Cross-Links Generated by <i>l,d</i> -Transpeptidation. <i>Journal of Bacteriology</i> , 2008, 190, 4360-4366. | 2.2 | 300 |
| 3 | Assessment of Clarithromycin Susceptibility in Strains Belonging to the <i>Mycobacterium abscessus</i> Group by <i>erm</i> (41) and <i>rrl</i> Sequencing. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 775-781. | 3.2 | 291 |
| 4 | Novel Gyrase Mutations in Quinolone-Resistant and -Hypersusceptible Clinical Isolates of <i>Mycobacterium tuberculosis</i> : Functional Analysis of Mutant Enzymes. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 104-112. | 3.2 | 176 |
| 5 | Detection by GenoType MTBDR <i>sl</i> Test of Complex Mechanisms of Resistance to Second-Line Drugs and Ethambutol in Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Complex Isolates. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1683-1689. | 3.9 | 170 |
| 6 | Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort. <i>Clinical Infectious Diseases</i> , 2015, 60, 188-194. | 5.8 | 165 |
| 7 | Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1011-1015. | 3.2 | 160 |
| 8 | Rapid Identification of Mycobacterial Whole Cells in Solid and Liquid Culture Media by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4481-4486. | 3.9 | 151 |
| 9 | Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3543-3547. | 3.2 | 127 |
| 10 | Performance of the Genotype MTBDR Line Probe Assay for Detection of Resistance to Rifampin and Isoniazid in Strains of <i>Mycobacterium tuberculosis</i> with Low- and High-Level Resistance. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3659-3664. | 3.9 | 116 |
| 11 | Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601799. | 6.7 | 112 |
| 12 | In Vivo Evaluation of Antibiotic Activity Against <i>Mycobacterium abscessus</i> . <i>Journal of Infectious Diseases</i> , 2014, 209, 905-912. | 4.0 | 89 |
| 13 | Rapid emergence of <i>Mycobacterium tuberculosis</i> bedaquiline resistance: lessons to avoid repeating past errors. <i>European Respiratory Journal</i> , 2017, 49, 1601719. | 6.7 | 86 |
| 14 | Molecular Investigation of Resistance to the Antituberculous Drug Ethionamide in Multidrug-Resistant Clinical Isolates of <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 355-360. | 3.2 | 80 |
| 15 | Comparing <i>Mycobacterium massiliense</i> and <i>Mycobacterium abscessus</i> lung infections in cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 63-69. | 0.7 | 80 |
| 16 | Fluoroquinolone-Containing Third-Line Regimen against <i>Mycobacterium tuberculosis</i> In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3117-3122. | 3.2 | 75 |
| 17 | Sterilizing Activity of R207910 (TMC207)-containing Regimens in the Murine Model of Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 553-557. | 5.6 | 74 |
| 18 | Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1029-1031. | 5.6 | 71 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4765-4771. | 3.2 | 70 |
| 20 | Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2019, 25, 936-943. | 4.3 | 68 |
| 21 | Extending the Definition of the GyrB Quinolone Resistance-Determining Region in <i>Mycobacterium tuberculosis</i> DNA Gyrase for Assessing Fluoroquinolone Resistance in <i>M. tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1990-1996. | 3.2 | 65 |
| 22 | A Once-Weekly R207910-containing Regimen Exceeds Activity of the Standard Daily Regimen in Murine Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 75-79. | 5.6 | 63 |
| 23 | Infections caused by <i>Mycobacterium abscessus</i> : epidemiology, diagnostic tools and treatment. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 1139-1154. | 4.4 | 63 |
| 24 | Rifabutin: where do we stand in 2016?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1759-1771. | 3.0 | 61 |
| 25 | Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis. <i>PLoS ONE</i> , 2011, 6, e17556. | 2.5 | 60 |
| 26 | Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for <i>Mycobacterium abscessus</i> with regard to subspecies and <i>erm41</i> sequevar. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2208-2212. | 3.0 | 54 |
| 27 | Selection of Resistance to Clarithromycin in <i>Mycobacterium abscessus</i> Subspecies. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 3.2 | 52 |
| 28 | Activity of Carbapenems Combined with Clavulanate against Murine Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2597-2600. | 3.2 | 51 |
| 29 | Molecular Analysis of the <i>embCAB</i> Locus and <i>embR</i> Gene Involved in Ethambutol Resistance in Clinical Isolates of <i>Mycobacterium tuberculosis</i> in France. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4800-4808. | 3.2 | 51 |
| 30 | Performance of the New Version (v2.0) of the GenoType MTBDR <i>sl</i> Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Complex Strains. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1573-1580. | 3.9 | 46 |
| 31 | Functional Analysis of DNA Gyrase Mutant Enzymes Carrying Mutations at Position 88 in the A Subunit Found in Clinical Strains of <i>Mycobacterium tuberculosis</i> Resistant to Fluoroquinolones. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 4170-4173. | 3.2 | 45 |
| 32 | Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1669-1677. | 3.0 | 44 |
| 33 | Bedaquiline plus delamanid for XDR tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 294. | 9.1 | 43 |
| 34 | Identification and Genotyping of <i>Mycobacterium tuberculosis</i> Complex Species by Use of a SNaPshot Minisequencing-Based Assay. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1758-1766. | 3.9 | 42 |
| 35 | Electronic Sensors for Assessing Interactions between Healthcare Workers and Patients under Airborne Precautions. <i>PLoS ONE</i> , 2012, 7, e37893. | 2.5 | 40 |
| 36 | Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 594-599. | 0.7 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union. <i>Eurosurveillance</i> , 2013, 18, 20555. | 7.0 | 37 |
| 38 | Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry-Based Single Nucleotide Polymorphism Genotyping Assay Using iPLEX Gold Technology for Identification of Mycobacterium tuberculosis Complex Species and Lineages. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3292-3299. | 3.9 | 35 |
| 39 | Molecular Diagnosis of Fluoroquinolone Resistance in Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1519-1524. | 3.2 | 35 |
| 40 | Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 167-174. | 1.2 | 34 |
| 41 | Comparison of methods available for identification of Mycobacterium chimaera. <i>Clinical Microbiology and Infection</i> , 2018, 24, 409-413. | 6.0 | 34 |
| 42 | Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. <i>International Journal of Tuberculosis and Lung Disease</i> , 2009, 13, 260-5. | 1.2 | 31 |
| 43 | Safety and efficacy of exposure to bedaquiline+delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. <i>European Respiratory Journal</i> , 2018, 51, 1702550. | 6.7 | 30 |
| 44 | Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France. <i>Emerging Infectious Diseases</i> , 2020, 26, 1792-1800. | 4.3 | 30 |
| 45 | Multidrug and extensively drug-resistant tuberculosis. <i>Médecine Et Maladies Infectieuses</i> , 2017, 47, 3-10. | 5.0 | 26 |
| 46 | Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2326-2333. | 3.0 | 24 |
| 47 | Clinical, Radiological, and Microbiological Characteristics of Mycobacterium simiae Infection in 97 Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 3.2 | 24 |
| 48 | Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a CyrB mutant causing fluoroquinolone resistance. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2007, 26, 423-425. | 2.9 | 23 |
| 49 | Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman. <i>Emerging Infectious Diseases</i> , 2017, 23, 1731-1732. | 4.3 | 23 |
| 50 | Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005066. | 3.0 | 23 |
| 51 | Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis. <i>BMC Infectious Diseases</i> , 2014, 14, 18. | 2.9 | 22 |
| 52 | Impact of Fluoroquinolone Resistance on Bactericidal and Sterilizing Activity of a Moxifloxacin-Containing Regimen in Murine Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4496-4500. | 3.2 | 20 |
| 53 | Unbiased Estimation of Mutation Rates under Fluctuating Final Counts. <i>PLoS ONE</i> , 2014, 9, e101434. | 2.5 | 20 |
| 54 | Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2016, 48, 582-585. | 6.7 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond. <i>Pulmonology</i> , 2018, 24, 132-141. | 2.1 | 19 |
| 56 | Efficient Intermittent Rifapentine-Moxifloxacin-Containing Short-Course Regimen for Treatment of Tuberculosis in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4015-4019. | 3.2 | 18 |
| 57 | Impact of a 14-year screening programme on tuberculosis transmission among the homeless in Paris. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 649-655. | 1.2 | 17 |
| 58 | Revisiting Species Identification within the <i>Enterobacter cloacae</i> Complex by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry. <i>Microbiology Spectrum</i> , 2021, 9, e0066121. | 3.0 | 17 |
| 59 | Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of <i>Mycobacterium tuberculosis</i> s in France. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 3.2 | 16 |
| 60 | Relapsing <i>Mycobacterium Genavense</i> Infection as a Cause of Late Death in a Lung Transplant Recipient: Case Report and Review of the Literature. <i>Experimental and Clinical Transplantation</i> , 2012, 10, 618-620. | 0.5 | 16 |
| 61 | Significant Difference in Drug Susceptibility Distribution between <i>Mycobacterium avium</i> and <i>Mycobacterium intracellulare</i> . <i>Journal of Clinical Microbiology</i> , 2014, 52, 4439-4440. | 3.9 | 15 |
| 62 | Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. <i>European Respiratory Journal</i> , 2022, 59, 2200166. | 6.7 | 15 |
| 63 | Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. <i>European Respiratory Journal</i> , 2022, 59, 2200388. | 6.7 | 15 |
| 64 | Osteomyelitis of the wrist caused by <i>Mycobacterium arupense</i> in an immunocompetent patient: a unique case. <i>International Journal of Infectious Diseases</i> , 2012, 16, e761-e762. | 3.3 | 14 |
| 65 | Empyema of the thorax due to <i>Gemella haemolysans</i> . <i>Journal of Infection</i> , 1999, 39, 245-246. | 3.3 | 13 |
| 66 | <i>Mycobacterial</i> infection of breast prosthesis – a conservative treatment: a case report. <i>BMC Infectious Diseases</i> , 2014, 14, 238. | 2.9 | 13 |
| 67 | Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 54-59. | 1.2 | 12 |
| 68 | Cutaneous miliary resistant tuberculosis in a patient infected with human immunodeficiency virus: case report and literature review. <i>Clinical and Experimental Dermatology</i> , 2009, 34, e690-e692. | 1.3 | 11 |
| 69 | Resistance of <i>M. leprae</i> to Quinolones: A Question of Relativity?. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2559. | 3.0 | 11 |
| 70 | Clonal Relationship and Differentiation among <i>Mycobacterium abscessus</i> Isolates as Determined Using the Semiautomated Repetitive Extragenic Palindromic Sequence PCR-Based DiversiLab System. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1969-1977. | 3.9 | 11 |
| 71 | XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions. <i>Médecine Et Maladies Infectieuses</i> , 2016, 46, 52-55. | 5.0 | 11 |
| 72 | Molecular detection methods of resistance to antituberculosis drugs in <i>Mycobacterium tuberculosis</i> . <i>Médecine Et Maladies Infectieuses</i> , 2017, 47, 340-348. | 5.0 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective. <i>Future Microbiology</i> , 2020, 15, 779-799. | 2.0 | 11 |
| 74 | Isoniazid-mono-resistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. <i>International Journal of Infectious Diseases</i> , 2021, 107, 86-91. | 3.3 | 11 |
| 75 | Assessing Primary and Secondary Resistance to Clarithromycin and Amikacin in Infections Due to <i>Mycobacterium avium</i> Complex. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7153-7155. | 3.2 | 10 |
| 76 | Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009-2014. <i>Emerging Infectious Diseases</i> , 2016, 22, 518-521. | 4.3 | 10 |
| 77 | Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 99-104. | 1.2 | 10 |
| 78 | Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 1050-1054. | 1.2 | 10 |
| 79 | Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with <i>Mycobacterium ulcerans</i> after only 16 doses. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007857. | 3.0 | 10 |
| 80 | Increase in primary drug resistance of <i>Mycobacterium tuberculosis</i> in younger birth cohorts in France. <i>Journal of Infection</i> , 2012, 64, 589-595. | 3.3 | 9 |
| 81 | Comparison of a Semiautomated Commercial Repetitive-Sequence-Based PCR Method with Spoligotyping, 24-Locus Mycobacterial Interspersed Repetitive-Unit-Variable-Number Tandem-Repeat Typing, and Restriction Fragment Length Polymorphism-Based Analysis of IS6110 for <i>Mycobacterium tuberculosis</i> Typing. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4082-4086. | 3.9 | 9 |
| 82 | Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in <i>Mycobacterium tuberculosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2428-2431. | 3.0 | 9 |
| 83 | In vivo <i>Mycobacterium tuberculosis</i> fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3465-3472. | 3.0 | 9 |
| 84 | <i>Mycobacterium boletii</i> Lung Disease in Cystic Fibrosis. <i>Chest</i> , 2019, 156, 247-254. | 0.8 | 9 |
| 85 | Rational Choice of Antibiotics and Media for <i>Mycobacterium avium</i> Complex Drug Susceptibility Testing. <i>Frontiers in Microbiology</i> , 2020, 11, 81. | 3.5 | 9 |
| 86 | Daptomycin is not active against rapidly growing mycobacteria. <i>Journal of Medical Microbiology</i> , 2010, 59, 135-136. | 1.8 | 8 |
| 87 | Non-tuberculous mycobacterial pulmonary diseases in France: an 8-year nationwide study. <i>BMC Infectious Diseases</i> , 2021, 21, 1165. | 2.9 | 8 |
| 88 | Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study. <i>Journal of Infection</i> , 2022, 84, 834-872. | 3.3 | 8 |
| 89 | Temporal interferon-gamma release response to <i>Mycobacterium kansasii</i> infection in an anorexia nervosa patient. <i>Journal of Medical Microbiology</i> , 2012, 61, 1617-1620. | 1.8 | 7 |
| 90 | Cavitary pulmonary disease in a patient treated with natalizumab. <i>Presse Medicale</i> , 2014, 43, 1009-1012. | 1.9 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Induction therapy with linezolid/clarithromycin combination for <i>Mycobacterium chelonae</i> skin infections in immunocompromised hosts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 101-105. | 2.4 | 6 |
| 92 | Estimation of pyrazinamidase activity using a cell-free <i>In vitro</i> synthesis of pncA and its association with pyrazinamide susceptibility in <i>Mycobacterium tuberculosis</i> . <i>International Journal of Mycobacteriology</i> , 2018, 7, 16. | 0.6 | 6 |
| 93 | Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting. <i>Clinical Microbiology and Infection</i> , 2015, 21, 472.e7-472.e10. | 6.0 | 5 |
| 94 | Impact of the revised definition of extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2021, 58, 2100641. | 6.7 | 5 |
| 95 | Nontuberculous <i>Mycobacteria</i> under Scrutiny in the Geneva Area (2015–2020). <i>Respiration</i> , 2022, 101, 367-375. | 2.6 | 5 |
| 96 | Evaluation of the Fluo-RAL Module for Detection of Tuberculous and Nontuberculous Acid-Fast Bacilli by Fluorescence Microscopy. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3469-3470. | 3.9 | 4 |
| 97 | Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv175. | 0.9 | 4 |
| 98 | Concomitant Multidrug-resistant Pulmonary Tuberculosis and Susceptible Tuberculous Meningitis. <i>Emerging Infectious Diseases</i> , 2014, 20, 506-507. | 4.3 | 3 |
| 99 | French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS [®] in MDR-TB Patients. <i>Chemotherapy</i> , 2014, 60, 174-179. | 1.6 | 3 |
| 100 | Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission. <i>European Respiratory Journal</i> , 2017, 50, 1700891. | 6.7 | 3 |
| 101 | Abdominal Tuberculosis: Experience from Two Tertiary-Care Hospitals in the Paris Region. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 223-228. | 1.4 | 3 |
| 102 | Fully weekly antituberculosis regimen: a proof-of-concept study. <i>European Respiratory Journal</i> , 2020, 56, 1902502. | 6.7 | 3 |
| 103 | National advisory services for multidrug-resistant tuberculosis (MDRTB) in Europe: an ERS-TBnet survey. , 2019, , . | | 3 |
| 104 | How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance. <i>Microorganisms</i> , 2022, 10, 1436. | 3.6 | 3 |
| 105 | Good Interpretation of the Results of a Diagnostic Test. <i>Clinical Infectious Diseases</i> , 2003, 37, 1143-1143. | 5.8 | 2 |
| 106 | Evaluation of data quality in a laboratory-based surveillance of <i>M. tuberculosis</i> drug resistance and impact on the prevalence of resistance: France, 2004. <i>Epidemiology and Infection</i> , 2008, 136, 1172-1178. | 2.1 | 2 |
| 107 | Retrospective review of <i>Pneumocystis jirovecii</i> pneumonia in a French intensive care unit (1994–2000). <i>International Journal of STD and AIDS</i> , 2009, 20, 441-442. | 1.1 | 2 |
| 108 | Performance of Quantiferon [®] for the diagnosis TB. <i>Médecine Et Maladies Infectieuses</i> , 2012, 42, 579-584. | 5.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Les nouveaux antituberculeux (1)Â: nouvelles utilisations de molÃ©cules existantes. Journal Des Anti-infectieux, 2013, 15, 95-101. | 0.1 | 2 |
| 110 | Characterization of a Clone of Mycobacterium tuberculosis Clinical Isolates with Mutations in KatG (A110V), EthA (Q269STOP), and the inhAPromoter (âˆ™15Câ†’T). Journal of Clinical Microbiology, 2015, 53, 3104-3104. | 3.9 | 2 |
| 111 | Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 783-793. | 3.0 | 2 |
| 112 | Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1489-1490. | 5.6 | 2 |
| 113 | Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1072-1073. | 5.6 | 2 |
| 114 | Bacillus Calmette-Guerin infection following intravesical instillation: Does the strain matter?. MÃ©decine Et Maladies Infectieuses, 2019, 49, 350-355. | 5.0 | 2 |
| 115 | Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen. Clinical Infectious Diseases, 2019, 68, 1410-1411. | 5.8 | 2 |
| 116 | Sampling strategy for bacteriological diagnosis of intrathoracic tuberculosis. Respiratory Medicine and Research, 2021, 79, 100825. | 0.6 | 2 |
| 117 | Voluminous pseudotumor due to Mycobacterium malmoeense. Presse Medicale, 2013, 42, 227-230. | 1.9 | 1 |
| 118 | In vivo selection of a multidrug-resistant <l>Mycobacterium avium</l> isolate in a patient with AIDS [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 141-142. | 1.2 | 1 |
| 119 | Should single antibiotic therapy be avoided for nontuberculous mycobacteria?. MÃ©decine Et Maladies Infectieuses, 2017, 47, 566-568. | 5.0 | 1 |
| 120 | First Whole-Genome Sequence of a Clinical Isolate of Multidrug-Resistant Mycobacterium bovis BCG. Genome Announcements, 2014, 2, . | 0.8 | 0 |
| 121 | Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies. European Respiratory Journal, 2021, 57, 2004315. | 6.7 | 0 |
| 122 | An expert statement on clinical considerations before treating NTM lung infection. , 2020, , . | | 0 |
| 123 | Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Microorganisms, 2022, 10, 1215. | 3.6 | 0 |